Ireland probes mistreatment at care homes run by French company
Representative AI image
DUBLIN: Ireland's health ministry Thursday ordered a probe into French care homes operator Emeis, the country's biggest private nursing home provider, after a television programme alleged residents in two places were mistreated.
The investigative programme aired undercover footage of elderly residents allegedly forced into chairs, and being ignored when they pleaded for help to go to the toilet.
The programme, shown on Irish state broadcaster RTE on Wednesday, also showed some residents were left in incontinence pads for so long their clothes were soaked.
The scenes were "extremely distressing" and "wholly unacceptable", health ministry official Kieran O'Donnell told RTE Thursday.
The ministry has ordered the Health Information and Quality Authority (HIQA) to launch a review of all nursing homes operated by Emeis, he said.
Offering its "sincere apologies", the firm said "this is not the standard of care it expects and not what residents and their families deserve", and pledged to review all operations across Ireland.
Emeis, which was called Orpea until last year, run 27 private nursing homes in Ireland.
The company entered the Irish market in 2020 through the takeover of another portfolio.
HIQA, who are tasked with inspecting care homes, said Emeis-run homes including the two featured in Wednesday's programme had triggered recent concerns.
Earlier this year, HIQA ordered one of them to cease admitting new residents, citing "significant concerns".
Minister for Enterprise Peter Burke told RTE an institution should not be operating "if people are not being cared for appropriately, with dignity, with respect".
"HIQA need to really enforce that and to ensure that everyone has a basic level of dignity and care that they deserve in their twilight years," said Burke.
Emeis changed its name to turn the page on a scandal in France when its homes came under scrutiny following the 2022 publication of the book "The Gravediggers" by independent journalist Victor Castan.
It cited employees and relatives claiming that residents were at times left for hours with soiled underwear or went days without care as managers sought to maximise profit margins.
Orpea contested those claims as "untruthful, scandalous and injurious".
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
a day ago
- Time of India
Ireland probes mistreatment at care homes run by French company
Representative AI image DUBLIN: Ireland's health ministry Thursday ordered a probe into French care homes operator Emeis, the country's biggest private nursing home provider, after a television programme alleged residents in two places were mistreated. The investigative programme aired undercover footage of elderly residents allegedly forced into chairs, and being ignored when they pleaded for help to go to the toilet. The programme, shown on Irish state broadcaster RTE on Wednesday, also showed some residents were left in incontinence pads for so long their clothes were soaked. The scenes were "extremely distressing" and "wholly unacceptable", health ministry official Kieran O'Donnell told RTE Thursday. The ministry has ordered the Health Information and Quality Authority (HIQA) to launch a review of all nursing homes operated by Emeis, he said. Offering its "sincere apologies", the firm said "this is not the standard of care it expects and not what residents and their families deserve", and pledged to review all operations across Ireland. Emeis, which was called Orpea until last year, run 27 private nursing homes in Ireland. The company entered the Irish market in 2020 through the takeover of another portfolio. HIQA, who are tasked with inspecting care homes, said Emeis-run homes including the two featured in Wednesday's programme had triggered recent concerns. Earlier this year, HIQA ordered one of them to cease admitting new residents, citing "significant concerns". Minister for Enterprise Peter Burke told RTE an institution should not be operating "if people are not being cared for appropriately, with dignity, with respect". "HIQA need to really enforce that and to ensure that everyone has a basic level of dignity and care that they deserve in their twilight years," said Burke. Emeis changed its name to turn the page on a scandal in France when its homes came under scrutiny following the 2022 publication of the book "The Gravediggers" by independent journalist Victor Castan. It cited employees and relatives claiming that residents were at times left for hours with soiled underwear or went days without care as managers sought to maximise profit margins. Orpea contested those claims as "untruthful, scandalous and injurious".
Business Standard
2 days ago
- Business Standard
Servier India introduces 'Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
VMPL Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication. Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40% of AML patients in India receive adequate treatment1, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced.2 The announcement marks a significant advancement in management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need. Speaking on the occasion, Mr. Aurelien Breton, Managing Director, Servier India, said, "Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most. By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch is a significant step forward in our mission to support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India." IDH1 mutation occurs in approximately 7-14% of AML patients in India3, making targeted mechanisms especially relevant for this subset. "This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.", highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India. Speaking on the importance of treatment access, Ms. Pratima Tripathi, Commercial Director, Servier India, said: "Our foremost priority is to ensure that the therapy is accessible and affordable to patients across India. We are actively collaborating with healthcare providers, patient advocacy groups, and policymakers to remove barriers and facilitate timely access to this important therapy. Through these partnerships, we are committed to expanding treatment options and making a meaningful difference in the lives of patients." By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patients. Disclaimer: This press release is intended solely to share regulatory and medical information regarding the launch; the reference to "Tibsovo" is not intended as a promotional or public advertisement. Use of the therapy is strictly based on a doctor's prescription and clinical discretion. About Servier India Servier India has been committed for over three decades to delivering innovative pharmaceutical solutions that improve the lives of patients and their families across India. Established in 1985 as an affiliate of the leading independent French pharmaceutical Servier Group, the company focuses on therapeutic areas such as Cardiometabolism, Neuroscience, Venous Diseases, and Oncology. Servier India has a strong pan-India presence and a dedicated workforce of around 580 that strives to address critical healthcare challenges with passion and purpose. As part of Servier group operating in over 150 countries, Servier India inherits a rich legacy of scientific excellence and patient-centric innovation. Globally, Servier invests heavily in research and development, focusing on our key therapeutic areas. About Servier Servier is a global pharmaceutical group governed by a Foundation that aspires to serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. As a world leader in cardiometabolism and venous diseases, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. Headquartered in France, Servier relies on a strong geographical footprint; its medicines are available in close to 140 group achieved a revenue of EUR5.9 billion in 2024. Additional Details on Ivosidenib Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea. In the United States, the US FDA approved it in 2019 as a monotherapy and later in May 2022 as a combination treatment with Azacitidine for patients aged 75 and above, or those who cannot tolerate intensive chemotherapy. The European Medical Agency (EMA) gave its approval in May 2023 for use in patients who are not fit for standard induction chemotherapy. In India, the process moved forward in April 2025, when the Subject Expert Committee (SEC) gave a positive recommendation for Ivosidenib. Following this, the DCGI granted approval for the marketing authorization in May 2025
Mint
2 days ago
- Mint
Israel-Backed Gaza Aid Group Suspends Operations for Second Day
An Israel- and US-backed mechanism to distribute food in Gaza suspended operations for a second day following a series of deadly incidents near its sites that drew international criticism. The Gaza Humanitarian Foundation, a Swiss-based nonprofit, launched in Gaza last week following a months-long Israeli blockade of the territory, and says it has handed out enough food staples for millions of meals. But the roll-out has been dogged by overcrowding and at least one incident in which Israeli forces, citing a security threat, fired toward Palestinians headed to a GHF aid center. 'The world is watching, day after day, horrifying scenes of Palestinians being shot, wounded or killed in Gaza while simply trying to eat,' Tom Fletcher, the UN humanitarian affairs chief, said in a statement urging Israel to allow his organization's aid network back into the territory. 'We must be allowed to do our jobs: We have the teams, the plan, the supplies and the experience.' UN Secretary General Antonio Guterres on Monday called for an independent investigation into reports that Israeli forces had killed dozens near the aid stations in Rafah. The Israeli army denied that its soldiers had shot anyone seeking aid and the GHF called the reports 'outright fabrications.' In a statement on June 2, the International Committee of the Red Cross said its hospital had received 21 dead among 179 casualties. The stations were shuttered on Wednesday and on Thursday morning 'due to ongoing maintenance and repair work,' the GHF said in a statement. It was not immediately clear when operations might resume. Gaza's 2 million Palestinians had long depended on UN relief before the Oct 7, 2023 Hamas attack that killed 1,200 people. During the almost 20-month-old war — in which more than 54,000 Palestinians have been killed, according to the Hamas-run health ministry — UN agencies have been sidelined by Israel, which accuses them of being too close to the US-designated terrorist group. Some of Israel's closest European allies, including Germany, the UK and France, have are increasingly critical of Israel's prosecution of the war, which has destroyed much of the coastal strip and sparked what international aid agencies say is a hunger crisis. They're considering trade sanctions and curbs on arms sales to push Israel to end the war. The UN has criticized the GHF for not being able to provide anywhere near enough food and medicine for Gaza's population and for politicizing humanitarian work. Israel, which controls Gaza's borders, argues that Hamas benefits from siphoning off UN aid. 'There is a joint effort here, both by Hamas and by the UN, which want to see the failure of these distribution centers,' Danny Danon, Israel's ambassador to the UN, said in an Army Radio interview on Thursday. This article was generated from an automated news agency feed without modifications to text.
